209 related articles for article (PubMed ID: 36480560)
1. The prognosis of lipid reprogramming with the HMG-CoA reductase inhibitor, rosuvastatin, in castrated Egyptian prostate cancer patients: Randomized trial.
Karkeet RM; Zekri AN; Sayed-Ahmed MM; Sherif GM; Salem SE; Abdelbary A; Fouad MA; Saad SY
PLoS One; 2022; 17(12):e0278282. PubMed ID: 36480560
[TBL] [Abstract][Full Text] [Related]
2. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.
Olsson AG; McTaggart F; Raza A
Cardiovasc Drug Rev; 2002; 20(4):303-28. PubMed ID: 12481202
[TBL] [Abstract][Full Text] [Related]
3. Atherogenic Lipoprotein Subfractions Determined by Ion Mobility and First Cardiovascular Events After Random Allocation to High-Intensity Statin or Placebo: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) Trial.
Mora S; Caulfield MP; Wohlgemuth J; Chen Z; Superko HR; Rowland CM; Glynn RJ; Ridker PM; Krauss RM
Circulation; 2015 Dec; 132(23):2220-9. PubMed ID: 26408274
[TBL] [Abstract][Full Text] [Related]
4. [Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation].
Polenova NV; Vaulin NA; Masenko VP; Iavelov IS; Gratsianskiĭ NA
Kardiologiia; 2009; 49(2):9-14. PubMed ID: 19254210
[TBL] [Abstract][Full Text] [Related]
5. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study.
Meek C; Wierzbicki AS; Jewkes C; Twomey PJ; Crook MA; Jones A; Viljoen A
Curr Med Res Opin; 2012 Mar; 28(3):371-8. PubMed ID: 22256801
[TBL] [Abstract][Full Text] [Related]
6. Association of Lipoproteins, Insulin Resistance, and Rosuvastatin With Incident Type 2 Diabetes Mellitus : Secondary Analysis of a Randomized Clinical Trial.
Dugani SB; Akinkuolie AO; Paynter N; Glynn RJ; Ridker PM; Mora S
JAMA Cardiol; 2016 May; 1(2):136-45. PubMed ID: 27347563
[TBL] [Abstract][Full Text] [Related]
7. Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
Deguchi I; Horiuchi Y; Hayashi T; Sehara Y; Kato Y; Ohe Y; Fukuoka T; Maruyama H; Sano H; Nagamine Y; Tanahashi N
J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2007-2011. PubMed ID: 25066602
[TBL] [Abstract][Full Text] [Related]
8. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
Ferdinand KC; Davidson MH; Kelly MT; Setze CM
Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
[TBL] [Abstract][Full Text] [Related]
9. Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).
Khera AV; Demler OV; Adelman SJ; Collins HL; Glynn RJ; Ridker PM; Rader DJ; Mora S
Circulation; 2017 Jun; 135(25):2494-2504. PubMed ID: 28450350
[TBL] [Abstract][Full Text] [Related]
10. Prevention of atherosclerosis in patients living with HIV.
De Lorenzo F; Boffito M; Collot-Teixeira S; Gazzard B; McGregor JL; Shotliff K; Xiao H
Vasc Health Risk Manag; 2009; 5(1):287-300. PubMed ID: 19436663
[TBL] [Abstract][Full Text] [Related]
11. High-dose statin therapy with rosuvastatin reduces small dense LDL and MDA-LDL: The Standard versus high-dose therApy with Rosuvastatin for lipiD lowering (SARD) trial.
Nishikido T; Oyama J; Keida T; Ohira H; Node K
J Cardiol; 2016 Apr; 67(4):340-6. PubMed ID: 26162946
[TBL] [Abstract][Full Text] [Related]
12. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
13. Comparative effects of high-dose atorvastatin versus moderate-dose rosuvastatin on lipid parameters, oxidized-LDL and inflammatory markers in ST elevation myocardial infarction.
Aydin MU; Aygul N; Altunkeser BB; Unlu A; Taner A
Atherosclerosis; 2015 Apr; 239(2):439-43. PubMed ID: 25697576
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of rosuvastatin in heart transplant patients with hypercholesterolemia and therapeutic failure of other statin regimens: short-term and long-term efficacy and safety results.
Barge-Caballero G; Barge-Caballero E; Marzoa-Rivas R; Paniagua-Martín MJ; Barrio-Rodríguez A; Naya-Leira C; Blanco-Canosa P; Grille-Cancela Z; Vázquez-Rodríguez JM; Crespo-Leiro MG
Transpl Int; 2015 Sep; 28(9):1034-41. PubMed ID: 25864881
[TBL] [Abstract][Full Text] [Related]
15. Are HIV positive patients resistant to statin therapy?
Johns KW; Bennett MT; Bondy GP
Lipids Health Dis; 2007 Oct; 6():27. PubMed ID: 17958912
[TBL] [Abstract][Full Text] [Related]
16. A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia.
Karlson BW; Palmer MK; Nicholls SJ; Lundman P; Barter PJ
Am J Cardiol; 2016 May; 117(9):1444-8. PubMed ID: 26969416
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Adding Omega-3 Fatty Acids in Statin-treated Patients with Residual Hypertriglyceridemia: ROMANTIC (Rosuvastatin-OMAcor iN residual hyperTrIglyCeridemia), a Randomized, Double-blind, and Placebo-controlled Trial.
Kim CH; Han KA; Yu J; Lee SH; Jeon HK; Kim SH; Kim SY; Han KH; Won K; Kim DB; Lee KJ; Min K; Byun DW; Lim SW; Ahn CW; Kim S; Hong YJ; Sung J; Hur SH; Hong SJ; Lim HS; Park IB; Kim IJ; Lee H; Kim HS
Clin Ther; 2018 Jan; 40(1):83-94. PubMed ID: 29223557
[TBL] [Abstract][Full Text] [Related]
18. Effects of Fixed-dose Combination of Low-intensity Rosuvastatin and Ezetimibe Versus Moderate-intensity Rosuvastatin Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia: A Randomized, Double-blind, Multicenter, Phase III Study.
Lee SA; Kim W; Hong TJ; Ahn Y; Kim MH; Hong SJ; Kim BS; Kim SY; Chae IH; Kim BJ; Rhee MY; Shin JH; Kang TS; Cho JM; Kim JS; Lee CW
Clin Ther; 2021 Sep; 43(9):1573-1589. PubMed ID: 34429197
[TBL] [Abstract][Full Text] [Related]
19. Rosuvastatin: a high-potency HMG-CoA reductase inhibitor.
Lopez LM
J Am Pharm Assoc (2003); 2005; 45(4):503-13. PubMed ID: 16128507
[TBL] [Abstract][Full Text] [Related]
20. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
